Filing Details
- Accession Number:
- 0001317757-11-000007
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-02-28 16:03:33
- Reporting Period:
- 2011-02-24
- Filing Date:
- 2011-02-28
- Accepted Time:
- 2011-02-28 16:03:33
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
792977 | Amag Pharmaceuticals Inc. | AMAG | In Vitro & In Vivo Diagnostic Substances (2835) | 042742593 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1296999 | David Arkowitz | C/O Amag Pharmaceuticals, Inc. 100 Hayden Avenue Lexington MA 02421 | Evp, Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2011-02-24 | 1,875 | $0.00 | 3,011 | No | 4 | C | Direct | |
Common Stock | Disposition | 2011-02-24 | 500 | $17.10 | 2,511 | No | 4 | S | Direct | |
Common Stock | Disposition | 2011-02-24 | 2,205 | $17.06 | 306 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Restricted Stock Unit | Acquisiton | 2011-02-24 | 1,875 | $0.00 | 1,875 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
1,875 | No | 4 | C | Direct |
Footnotes
- The shares were acquired by the reporting person as a result of the partial vesting of a restricted stock unit grant described below.
- Not applicable.
- The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- Each restricted stock unit represents a contingent right to receive one share of common stock.
- Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments on February 24, 2011, February 24, 2012, February 24, 2013 and February 24, 2014.